Opella

Opella

Global OTC & VMS self-care manufacturer

Overview

Opella produces over-the-counter medicines, vitamins, minerals and supplements for a global audience, with about 100 brands and 11,000 employees. Its products are ready-to-use self-care remedies sold without prescription, covering needs like pain relief, digestion and allergy relief. The company differentiates itself through a large global manufacturing footprint (13 sites) and dedicated science and innovation centers, plus its status as a certified B Corp focused on health for people and the planet. Its goal is to simplify self-care, putting health in people’s hands for half a billion consumers and growing its trusted portfolio through manufacturing excellence and science-backed development.

Significant Headcount Growth

About Opella

Simplify's Rating
Why Opella is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Consumer Goods

Company Size

5,001-10,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Neuilly-sur-Seine, France

Founded

2018

Get referred to Opella

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2026 Ocoyoacoy plant adds 200 million Enterogermina mini-bottles yearly.
  • Opella targeted 80% local Mexican manufacturing, cutting logistics costs and improving resilience.
  • May 2026 debt repricing lowered Opella borrowing costs on roughly €4.97 billion facilities.

What critics are saying

  • July 2026 Mucosolvan shortages in Brazil expose brittle sourcing and supply continuity.
  • June 2026 Pharmaton counterfeiting in Mexico damages trust and invites tighter regulator scrutiny.
  • If Enterogermina migration to Mexico slips, Americas supply and growth plans stall.

What makes Opella unique

  • Opella owns 100 brands and 13 manufacturing sites across OTC and VMS.
  • 2025 carve-out from Sanofi creates a focused consumer-health platform with independent execution.
  • Enterogermina, Allegra, Doliprane, and Buscopan give Opella household-name shelf power.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

↑ 77%

1 year growth

↑ 77%

2 year growth

↑ 27%
Technology Magazine
Sep 9th, 2026
Procurement LIVE: Opella fixes broken processes with AI.

Procurement LIVE: Opella fixes broken processes with AI. September 09, 2026 Lyvio Frimat, Vice President and Global Head of Procurement COE at Opella, warns against "marketing AI" without fixing core operational models first Procurement leaders are navigating a period of unprecedented digital disruption, but true progress requires addressing a fundamental mindset shift. "Senior leaders fear AI," declared Lyvio Frimat, Vice President and Global Head of Procurement Centre of Excellence (COE), Strategy & Transformation at pharmaceutical company Opella, during a session at Procurement LIVE: The London Summit, a BizClik event, today. "Most of the time when we do implement AI, it's not because we wanted to do it, it's because at some point it was a top-down decision." For Lyvio, this anxiety stems from a form of FOMO - not just the fear of missing out, but the fear of being missed out. Recognising this anxiety is the first step toward building operating models designed not for current executive tenures, but for the next generation of digital-native talent. Earning a seat at the table. In many organisations, procurement continues to fight for executive visibility, but Lyvio believes that effort is misplaced. "Procurement is indeed becoming strategic, but we don't own a seat at the table," he said. "We become strategic by the time when people are around the table, they start a conversation and then stop and say, 'Hey, where's the procurement guy?'". Achieving that level of influence requires moving past surface-level technology adoption - what Lyvio provocatively calls "marketing AI". Most of the time, Technology Magazine is putting a pot of flour on top of a very bad smell - Technology Magazine think it's going to work, but most of the time it fails. Technology Magazine will never be able to fix processes by putting tools in to replace them. Lyvio Frimat, Vice President and Global Head of Procurement Centre of Excellence (COE), Strategy & Transformation at Opella Getting your hands dirty. Deploying digital tools over broken processes yields predictable failures. "Most of the time, we are putting a pot of flour on top of a very bad smell - we think it's going to work, but most of the time it fails," Lyvio explained. "We will never be able to fix processes by putting tools in to replace them." Instead, procurement teams must build deep technical literacy to understand how systems function and what operational shifts are required to support them. "The hard way is sometimes to have your hands in the dirt, understanding the technology," he noted. To drive this transformation effectively, Opella structures its strategy around rigid operational foundations where governance comes first, backed by human intelligence alongside AI rather than the reverse. Under this framework, the entire procure tech landscape is directly owned by the COE team to ensure that every technology choice tightly aligns with the overarching architecture. By keeping humans firmly in control, automated agents manage standard operating procedures while human experts handle complex exceptions and focus on high-value decision-making. By fixing core operating models first, procurement moves beyond basic cost savings to unlock total value contribution - surfacing risk mitigation, supplier innovation and long-term capability building. Building the agentic procurement COE. Moving from theoretical strategy to practical execution requires redefining the relationship between enterprise technology and human expertise. At Opella, the Center of Excellence (COE) enforces strict process standards before layering software over operational workflows. Rather than treating AI as an end-to-end replacement for human judgment, the organisation uses digital agents to process standard operating procedures, data verification and routine compliance checks. This structural hierarchy ensures that human experts retain full visibility over edge cases and strategic vendor negotiations. By elevating procurement teams from transactional oversight to governance leads, organisations eliminate executive friction and establish sustainable, audit-ready operating models suited for the next generation of digital-native leaders. Key Opella brands. * Allegra: A leading non-drowsy antihistamine brand used globally to treat seasonal allergy and fever symptoms. * Buscopan: An antispasmodic medication widely used to relieve abdominal pain, cramping, and IBS symptoms. * Doliprane: A household paracetamol brand in France, used for pain relief and fever management. * Dulcolax: A widely recognized over-the-counter brand providing targeted constipation relief solutions. * Mucosolvan: A popular respiratory health brand offering cough relief and mucus-clearing treatments. Company Portals

Creative Brands
Jul 30th, 2026
Karan Bhatia joins Asahi Group as director-agps.

Karan Bhatia joins Asahi Group as director-agps. Karan Bhatia has transitioned from Sanofi and Opella to join Asahi Group as Director-AGPS. Announcing the move on LinkedIn, he reflected on closing a nine-year chapter with the two organisations, expressing gratitude for the experiences and opportunities gained during his tenure. Karan Bhatia has embarked on a new professional journey, joining Asahi Group as Director-AGPS after nearly a decade with Sanofi and its subsidiary Opella. The development was shared by Bhatia in a LinkedIn update, where he confirmed his departure from the pharmaceutical giant and expressed appreciation for the formative years he spent across the two organisations. "Last week, I closed a professional chapter of nine years with Sanofi & Opella. I'm grateful for my time in these two world-class organisations," he wrote, signalling both the end of a significant tenure and the beginning of a fresh chapter with Asahi Group. Bhatia's move marks a notable shift from the healthcare and pharmaceutical sector to the global beverage industry, underscoring the breadth of his professional expertise and adaptability. Sanofi, a multinational pharmaceutical company headquartered in Paris, and Opella, its consumer healthcare arm, provided him with a platform to contribute to diverse markets and complex business environments. His nine-year association with the two companies reflects a period of sustained growth and leadership, during which he played a role in advancing business strategies and operational excellence. The transition to Asahi Group, a leading Japanese beverage and food company with a strong international footprint, positions Bhatia within a dynamic sector known for innovation and global consumer engagement. As Director-AGPS, he is expected to bring his extensive experience in corporate leadership, strategic planning and cross-sectoral collaboration to strengthen Asahi's global operations. Industry observers note that such cross-sectoral moves are increasingly common among senior executives, reflecting the convergence of skills required across industries. Bhatia's background in healthcare and pharmaceuticals equips him with a unique perspective on consumer needs, regulatory frameworks and international business practices, which are highly relevant to the fast-evolving beverage industry. His announcement has drawn attention within professional circles, with peers and colleagues acknowledging his contributions to Sanofi and Opella while extending best wishes for his new role. The move also highlights the growing trend of leaders leveraging their expertise across diverse industries to drive transformation and growth. For Asahi Group, the appointment underscores its commitment to strengthening leadership capabilities and enhancing its global strategy. For Bhatia, it represents both continuity and change: continuity in his pursuit of impactful leadership, and change in embracing new challenges within a different sector. Discover more from creative brands mag. Brand Management Discover more advertising Business Operations Missing Persons & Abductions July 30, 2026 Discover more Shopping Portals

Mexico Business News
Jul 24th, 2026
The Week in Health: Hospital investment, Cyclospora Outbreak.

The Week in Health: Hospital investment, Cyclospora Outbreak. By Sergio Arturo Lievano Madrigal | Journalist - Fri, 07/24/2026 - 09:59 DIA assistant Mexico's health sector moved on two fronts this week: public infrastructure spending and private manufacturing investment both accelerated, while a cross-border food safety scare tested coordination with the FDA. Meanwhile, a cholesterol drug approval and an insurtech's growth rounded out a week defined by expanding access to care. Ready? This is the Week in Health! Mexico Unveils MX$181 Billion Hospital Infrastructure Plan The government will invest close to MX$181 billion through 2030 to build, expand, or replace 152 public hospitals, growing the IMSS, ISSSTE, and IMSS Bienestar network past 106,000 beds. The plan responds to long-documented funding disparities across Mexico's fragmented public health subsystems. Mexico Modernizes Public Hospitals as Medical Device Market Grows ISSSTE's MX$298 million investment in electric beds and operating room upgrades coincides with LINET Group's new Santa Fe headquarters, signaling sustained demand for medical equipment. Together, the moves point to a multi-front procurement cycle spanning commodity and specialized devices alike. Mexico Investigates Cyclospora Outbreak Mexican authorities activated a joint task force with the FDA to investigate a cyclospora outbreak linked to lettuce from Guanajuato-based supplier Taylor Farms. The case carries real stakes for Mexico's vegetable export sector, which sends nearly 96% of its output to the United States. FDA Approves Merck Oral Pill for High Cholesterol The US FDA approved Lipfendra, Merck's first-in-class oral PCSK9 inhibitor, aimed at the 70% of statin patients who still miss their cholesterol targets. The approval carries relevance for Mexico, where cardiovascular disease remains a leading cause of mortality. Opella Expands Enterogermina Production Line in State of Mexico Opella inaugurated a MX$1.2 billion production line in Ocoyoacac, part of a MX$2.3 billion plan to raise local manufacturing for the domestic market to 80%. The project positions the site as a global backup facility and is expected to create 500 direct and indirect jobs. Disrupting Mexican Healthcare Through Tech-Driven InsurTech Mutuus' Jean-Louis Brunet tells MBN the insurtech now serves 14,000 members through a zero-deductible, direct-payment model targeting Mexico's underserved middle class. He says recent IVA tax changes forced a 23% workforce cut, even as the company grows more than 40% annually.

Logistics Manager
Jul 24th, 2026
Opella inaugurates new $70m-backed production line.

Opella inaugurates new $70m-backed production line. Healthcare company Opella has announced that it has inaugurated a new production line for Enterogermina in Mexico following a US$70 million (c. £52m) investment. Reportedly, the highly automated facility in Ocoyoacac will add an annual capacity of 200 million mini-bottles. It will serve as a complementary regional hub to Opella's plant in Origgio, Italy, and will operate on 100% renewable electrical energy. Opella chief supply chain officer, Rafik Amrane, said: "This new production line in Mexico is a crucial step forward in its broader mission to build a highly resilient, global manufacturing network. "By increasing our production capacity and being closer to the markets we serve, we are fundamentally changing how we deliver care, ensuring that our science-backed solutions are consistently available to the millions of families who rely on them." Following rigorous qualification and regulatory approvals, the new production line will progressively scale operations to bring the product to shelves across the Americas in the 2027-2028 period. Opella Mexico general manager, Luis Soares, said: "With this new production line, Logistics Manager is strengthening Mexico's role as a strategic platform for advanced pharmaceutical manufacturing and exports to Latin America. "It will also enable us to increase the share of Opella products sold in Mexico that are locally manufactured from 60% to 80%, combining stronger, sustainable local production with greater regional reach." IntraLogisteX is taking place in Dallas in 2026, bringing the industry's leading trade show & conference to one of North America's most important logistics hubs. Reuben joined Akabo Media as assistant editor of CiTTi - one of Logistics Manager's sister publications - in October 2023. He has worked in digital and print publications since graduating in MA Publishing in 2022. He holds a great interest in transport technology and innovation. Outside of work, Reuben is also a huge football fan. 24th July 2026 21st July 2026

MEXICONOW
Jul 23rd, 2026
Opella shifts Enterogermina production to Mexico.

Opella shifts Enterogermina production to Mexico. 23 July, 2026 Opella has transferred production of its flagship probiotic Enterogermina from Italy to Mexico, marking a major milestone in the company's manufacturing strategy for the Americas. The move is supported by a US$70 million investment in a new production line at its Ocoyoacac facility in the State of Mexico, part of a broader US$135 million expansion plan running through 2028. The expansion transforms the Ocoyoacac plant into the company's second global manufacturing hub for Enterogermina, complementing its long-established facility in Origgio, Italy. For the first time, the Mexican site will produce both the active pharmaceutical ingredient and the finished product, bringing advanced manufacturing capabilities that were previously concentrated in Europe. The new production line adds an annual capacity of 200 million mini-bottles, enabling Opella to meet growing demand across Latin America while strengthening the resilience of its global supply network. Company executives said producing closer to key markets will improve supply chain efficiency and support faster regional distribution. As production ramps up, the share of Opella products sold in Mexico that are manufactured locally will increase from 60% to 80%. The company also expects the facility to play a larger role as an export platform, supplying multiple Latin American markets from Mexico. Beyond expanding manufacturing capacity, the investment includes a significant transfer of industrial expertise and production technology. According to the company, the project equips the Mexican operation with specialized know-how and quality systems required to manufacture one of the world's leading probiotic brands under the same standards applied in Europe. The Ocoyoacac facility also supports Opella's sustainability objectives. The site operates with 100% renewable electricity, has significantly reduced carbon emissions over the past several years, and follows a zero-waste-to-landfill model, aligning manufacturing expansion with the company's environmental commitments. With the relocation of Enterogermina production, Mexico assumes a more strategic role within Opella's global manufacturing network, reinforcing the country's position as an emerging pharmaceutical production and export hub for the Americas.

Recently Posted Jobs

Sign up to get curated job recommendations

Opella is Hiring for 22 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →